Abstract
Abnormalities within normal–appearing grey and white matter (NAGM and NAWM) occur early in the clinical course of multiple sclerosis (MS) and can be detected in–vivo using the magnetisation transfer ratio (MTR). To better characterize the rates of change in both tissues and to ascertain when such changes begin, we serially studied a cohort of minimally disabled, early relapsing–remitting MS patients, using NAGM and NAWM MTR histograms. Twenty–three patients with clinically definite early relapsing–remitting MS (mean disease duration at baseline 1.9 years), and 19 healthy controls were studied. A magnetisation transfer imaging sequence was acquired yearly for two years. Twenty–one patients and 10 controls completed followup. NAWM and NAGM MTR histograms were derived and mean MTR calculated. A hierarchical regression analysis, adjusting for brain parenchymal fraction,was used to assess MTR change over time. MS NAWM and NAGM MTR were significantly reduced in comparison with controls at baseline and, in patients, both measures decreased further during follow–up: (–0.10pu/year, p = 0.001 and –0.18pu/year, p < 0.001 respectively). The rate of MTR decrease was significantly greater in NAGM than NAWM (p = 0.004). Under the assumption that such changes are linear, backward extrapolation of the observed rates of change suggested that NAWM abnormality began before symptom onset. We conclude that increasing MTR abnormalities in NAWM and NAGM are observed early in the course of relapsing–remitting MS. It is now important to investigate whether these measures are predictive of future disability, and consequently, whether MTR could be used as a surrogate marker in therapeutic trials.
Similar content being viewed by others
References
Allen IV, McKeown SR (1979) A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci 41:81–91
Allen IV, McQuaid S, Mirakhur M, Nevin G (2001) Pathological abnormalities in the normal–appearing white matter in multiple sclerosis. Neurol Sci 22:141–144
Barker GJ, Tofts PS, Gass A (1996) An interleaved sequence for accurate and reproducible clinical measurement of magnetization transfer ratio. Magn Reson Imaging 14:403–411
Carpenter JR, Bithall JF (2000) Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med 19:1141–1164
Chard DT, Griffin CM, Parker GJ, Kapoor R, Thompson AJ, Miller DH (2002) Brain atrophy in clinically early relapsing–remitting multiple sclerosis. Brain 125:327–337
Chard DT, Parker GJ, Griffin CM, Thompson AJ, Miller DH (2002) The reproducibility and sensitivity of brain tissue volume measurements derived from an SPM–based segmentation methodology. J Magn Reson Imaging 15:259–267
Chard DT, Griffin CM, Rashid W, Davies GR, Altmann DR, Kapoor R, Barker GJ, Thompson AJ, Miller DH (2004) Progressive grey matter atrophy in clinically early relapsing–remitting multiple sclerosis. Mult Scler 10:387–391
Davies GR, Ramió–Torrentà L, Hadjiprocopis A, Chard DT, Griffin CM, Rashid W, Barker GJ, Kapoor R, Thompson AJ, Miller DH (2004) Evidence for grey matter MTR abnormality in minimally disabled patients with early relapsing–remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 75:998–1002
De Stefano N, Narayanan S, Francis SJ, Smith S, Mortilla M, Tartaglia MC, Bartolozzi ML, Guidi L, Federico A, Arnold DL (2002) Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability. Arch Neurol 59:1565–7151
Dousset V, Grossman RI, Ramer KN, Schnall MD, Young LH, Gonzalez– Scarano F, Lavi E, Cohen JA (1992) Experimental allergic encephalomyelitis and multiple sclerosis:lesion characterization with magnetization transfer imaging. Radiology 182:483–491
Evangelou N, Esiri MM, Smith S, Palace J, Matthews PM (2000) Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol 47:391–395
Filippi M, Campi A, Dousset V, Baratti C, Martinelli V, Canal N, Scotti G, Comi G A (1995) Magnetization transfer imaging study of normal–appearing white matter in multiple sclerosis. Neurology 45:478–482
Filippi M, Rocca MA, Martino G, Horsfield MA, Comi G (1998) Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in multiple sclerosis. Ann Neurol 43:809–814
Filippi M, Iannucci G, Tortorella C, Minicucci L, Horsfield MA, Colombo B, Sormani MP, Comi G (1999) Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI. Neurology 52:588–594
Filippi M, Inglese M, Rovaris M, Sormani MP, Horsfield P, Iannucci PG, Colombo B, Comi G (2000) Magnetization transfer imaging to monitor the evolution of MS: a 1–year follow–up study. Neurology 55:940–946
Filippi M, Dousset V, McFarland HF, Miller DH, Grossman RI (2002) Role of magnetic resonance imaging in the diagnosis and monitoring of multiple sclerosis:consensus report of the White Matter Study Group. J Magn Reson Imaging 15:499–504
Fischer JS, Jak AJ, Kniker JE, Rudick RA, Cutter G (1999) Administration and scoring manual for the multiple sclerosis functional composite measure (MSFC). National Multiple Sclerosis Society. Demos Medical Publishing, New York
Gareau PJ, Rutt BK, Karlik SJ, Mitchell JR (2000) Magnetization transfer and multicomponent T2 relaxation measurements with histopathologic correlation in an experimental model of MS. J Magn Reson Imaging 11:586–595
Goldstein H (1995) Multilevel statistical models. Arnold, London
Griffin CM, Chard DT, Parker GJ, Barker GJ, Thompson AJ, Miller DH (2002) The relationship between lesion and normal appearing brain tissue abnormalities in early relapsing remitting multiple sclerosis. J Neurol 249:193–199
Iannucci G, Tortorella C, Rovaris M, Sormani MP, Comi G, Filippi M (2000) Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. AJNR Am J Neuroradiol 21:1034–1038
The IFNB Multiple Sclerosis Study Group (1993) Interferon beta–1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, doubleblind, placebo–controlled trial. Neurology 43:655–666
Inglese M, van Waesberghe JH, Rovaris M, Beckmann K, Barkhof F, Hahn D, Kappos L, Miller DH, Polman C, Pozzilli C, Thompson AJ, Yousry TA, Wagner K, Comi G, Filippi M (2003) The effect of interferon beta–1b on quantities derived from MT MRI in secondary progressive MS Neurology 60:853–860
Kalkers NF, Vrenken H, Uitdehaag BM, Polman CH, Barkhof F (2002) Brain atrophy in multiple sclerosis:impact of lesions and damage of whole brain tissue. Mult Scler 8:410–414
Kidd D, Barkhof F, McConnell R, Algra PR, Allen IV, Revesz T (1999) Cortical lesions in multiple sclerosis. Brain 122:17–26
Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis:an expanded disability status scale (EDSS). Neurology 33:1444–1452
Laule C, Vavasour IM, Whittall KP, Oger J, Paty DW, Li DK, MacKay AL, Arnold DL (2003) Evolution of focal and diffuse magnetisation transfer abnormalities in multiple sclerosis. J Neurol 250:924–931
Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis:results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907–911
Molyneux PD, Barker GJ, Barkhof F, Beckmann K, Dahlke F, Filippi M, Ghazi M, Hahn D, MacManus D, Polman C, Pozzilli C, Kappos L, Thompson AJ, Wagner K, Yousry T, Miller DH (2001) Clinical–MRI correlations in a European trial of interferon beta–1b in secondary progressive MS. Neurology 57:2191–2197
Mottershead JP, Schmierer K, Clemence M, Thornton JS, Scaravilli F, Barker GJ, Tofts PS, Newcombe J, Cuzner ML, Ordidge RJ, McDonald WI, Miller DH (2003) High field MRI correlates of myelin content and axonal density in multiple sclerosis:a post mortem study of spinal cord. J Neurol 250:1293–1301
Paty D, Li, DK, the UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group (1993) Interferon beta–1b is effective in relapsing–remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, doubleblind, placebo–controlled trial. Neurology 43:662–667
Peterson JW, Bo L, Mork S, Chang A, Trapp BD (2001) Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 50:389–400
Plummer DL (1992) DispImage:a display and analysis tool for medical images. Revista Di Neuroradiologica 5:489–495
Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis:guidelines for research protocols. Ann Neurol 13:227–231
Rovaris M, Agosta F, Sormani MP, Inglese M, Martinelli V, Comi G, Filippi M (2003) Conventional and magnetisation transfer MRI predictors of clinical multiple sclerosis evolution:a medium–term follow–up study. Brain 126:2323–3332
Sailer M, O’Riordan JI, Thompson AJ, Kingsley DP, MacManus DG, McDonald WI, Miller DH (1999) Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology 52:599–606
Traboulsee A, Dehmeshki J, Brex PA, Dalton CM, Chard D, Barker GJ, Plant GT, Miller DH (2002) Normal–appearing brain tissue MTR histograms in clinically isolated syndromes suggestive of MS. Neurology 59:126–128
Traboulsee A, Dehmeshki J, Peters KR, Peters KR, Griffin CM, Brex PA, Silver N, Ciccarrelli O, Chard DT, Barker GJ, Thompson AJ, Miller DH (2003) Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities. Mult Scler 9:566–573
van Buchem MA, McGowan JC, Kolson DL, Polansky M, Grossman RI (1996) Quantitative volumetric magnetization transfer analysis in multiple sclerosis:estimation of macroscopic and microscopic disease burden. Magn Reson Med 36:632–636
van Buchem MA, Grossman RI, Armstrong C, Polansky M, Miki Y, Heyning FH, Boncoeur–Martel MP, Wei L, Udupa JK, Grossman M, Kolson DL, McGowan JC (1998) Correlation of volumetric magnetization transfer imaging with clinical data in MS. Neurology 50:1609–1617
van Waesberghe JH, Kamphorst W, De Groot CJ, van Walderveen MA, Castelijns JA, Ravid R, Nijeholt GJ, van d, V, Polman CH, Thompson AJ, Barkhof F (1999) Axonal loss in multiple sclerosis lesions:magnetic resonance imaging insights into substrates of disability. Ann Neurol 46:747–754
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Davies, G.R., Altmann, D.R., Hadjiprocopis, A. et al. Increasing normal–appearing grey and white matter magnetisation transfer ratio abnormality in early relapsing–remitting multiple sclerosis. J Neurol 252, 1037–1044 (2005). https://doi.org/10.1007/s00415-005-0808-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-005-0808-x